Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT)

Bone Marrow Transplant. 1991:7 Suppl 2:150.

Authors

D Blaise¹, D Guyotat, J Reiffers, D Olive, M Michallet, C Bellanger, J P Vernant, N Ifrah, M Attal, E Vilmer, et al.

Affiliation

¹ Institut Paoli Calmettes, Marseille, France.

PMID: 1878689

No abstract available

Publication types

Clinical Trial
Comparative Study
Multicenter Study
Randomized Controlled Trial

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Bone Marrow Transplantation / adverse effects*
Cyclosporins / therapeutic use
Graft vs Host Disease / prevention & control*
Humans
Immunosuppression Therapy / methods*
Leukemia / surgery
Methotrexate / therapeutic use
Prospective Studies
Receptors, Interleukin-2 / immunology*
Transplantation, Homologous

Substances

Antibodies, Monoclonal
Cyclosporins
Receptors, Interleukin-2
Methotrexate